BeyondSpring Inc. (BYSI)
NasdaqCM: BYSI
· Real-Time Price · USD
0.74
-0.05 (-6.33%)
At close: Aug 12, 2026, 3:59 PM
BeyondSpring Inc. (BYSI) Stock Price, Analysis & Data
-6.33% (1D)
| Bid | 0.55 |
| Market Cap | 30.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.18M |
| Beta | 0.12 |
| EPS (ttm) | -0.19 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.58 |
| P/B (ttm) | -0.88 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 13, 2026 |
| Ask | 0.97 |
| Volume | 32,900 |
| Avg. Volume (20D) | 30,464 |
| Open | 0.80 |
| Previous Close | 0.79 |
| Day's Range | 0.73 - 0.80 |
| 52-Week Range | 0.73 - 2.44 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2017
Employees 44
Stock Exchange NasdaqCM
Ticker Symbol BYSI
Website https://beyondspringpharma.com
Financial Performance
In 2025, BeyondSpring's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.01M, a decrease of -90.96%.
Financial StatementsEarnings Surprise
BeyondSpring has released their quarterly earnings on Apr 14, 2022:
BeyondSpring Inc. is scheduled to release its earnings on Aug 13, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
